Andrew Tsai
Stock Analyst at Jefferies
(4.85)
# 377
Out of 4,604 analysts
165
Total ratings
63.1%
Success rate
29.8%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintained: Buy | $255 | $206.63 | +23.41% | 9 | Jul 30, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | $10 → $7.5 | $7.22 | +3.88% | 13 | Jul 17, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $200 → $380 | $212.85 | +78.53% | 3 | Jul 16, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $100 | $81.99 | +21.97% | 10 | Jul 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $550 | $319.23 | +72.29% | 8 | Jun 30, 2026 | |
| HELP Cybin | Maintained: Buy | $22 | $10.53 | +108.93% | 2 | Jun 25, 2026 | |
| DFTX Definium Therapeutics | Rated: Buy | $35 | $44.39 | -21.15% | 4 | Jun 22, 2026 | |
| MRNA Moderna | Maintained: Hold | $45 | $56.26 | -20.01% | 7 | Jun 16, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $18 | $13.58 | +32.55% | 2 | May 14, 2026 | |
| ANRO Alto Neuroscience | Maintained: Buy | $35 | $28.03 | +24.87% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $145 | $80.00 | +81.25% | 1 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $100 | $64.30 | +55.52% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $15.93 | +88.32% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 | $5.09 | +47.35% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.297 | +203.03% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $5 | $4.35 | +14.94% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $31.93 | -6.04% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $12.92 | +147.68% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $5.37 | +86.22% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 → $3 | $3.50 | -14.29% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $0.85 | $2.45 | n/a | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.5 | $5.51 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $46.91 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $42.44 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $7.62 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $5.44 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $26.17 | n/a | 5 | Jun 24, 2024 |
Biogen
Jul 30, 2026
Maintained: Buy
Price Target: $255
Current: $206.63
Upside: +23.41%
AtaiBeckley
Jul 17, 2026
Downgraded: Hold
Price Target: $10 → $7.5
Current: $7.22
Upside: +3.88%
Axsome Therapeutics
Jul 16, 2026
Maintained: Buy
Price Target: $200 → $380
Current: $212.85
Upside: +78.53%
BridgeBio Pharma
Jul 6, 2026
Maintained: Buy
Price Target: $100
Current: $81.99
Upside: +21.97%
Praxis Precision Medicines
Jun 30, 2026
Maintained: Buy
Price Target: $550
Current: $319.23
Upside: +72.29%
Cybin
Jun 25, 2026
Maintained: Buy
Price Target: $22
Current: $10.53
Upside: +108.93%
Definium Therapeutics
Jun 22, 2026
Rated: Buy
Price Target: $35
Current: $44.39
Upside: -21.15%
Moderna
Jun 16, 2026
Maintained: Hold
Price Target: $45
Current: $56.26
Upside: -20.01%
COMPASS Pathways
May 14, 2026
Maintained: Buy
Price Target: $18
Current: $13.58
Upside: +32.55%
Alto Neuroscience
May 14, 2026
Maintained: Buy
Price Target: $35
Current: $28.03
Upside: +24.87%
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $80.00
Upside: +81.25%
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $64.30
Upside: +55.52%
Jan 12, 2026
Maintained: Buy
Price Target: $35 → $30
Current: $15.93
Upside: +88.32%
Dec 31, 2025
Maintained: Hold
Price Target: $7.5
Current: $5.09
Upside: +47.35%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.297
Upside: +203.03%
Dec 1, 2025
Maintained: Hold
Price Target: $3 → $5
Current: $4.35
Upside: +14.94%
Nov 24, 2025
Maintained: Buy
Price Target: $30
Current: $31.93
Upside: -6.04%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $12.92
Upside: +147.68%
Nov 11, 2025
Maintained: Buy
Price Target: $10
Current: $5.37
Upside: +86.22%
Aug 8, 2025
Maintained: Hold
Price Target: $2.5 → $3
Current: $3.50
Upside: -14.29%
Aug 6, 2025
Maintained: Hold
Price Target: $3 → $0.85
Current: $2.45
Upside: n/a
Mar 26, 2025
Maintained: Buy
Price Target: $8.5
Current: $5.51
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $46.91
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $42.44
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $7.62
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $5.44
Upside: n/a
Jun 24, 2024
Maintained: Buy
Price Target: $42
Current: $26.17
Upside: n/a